## Contents

### Highlights of This Issue  1187

### SPECIAL FEATURES

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1189</td>
<td>PET Imaging of Tumor Growth: Not as Easy as It Looks</td>
<td>Anthony F. Shields</td>
<td>1303</td>
</tr>
<tr>
<td>1192</td>
<td>Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety</td>
<td>David L. Bajor and Robert H. Vonderheide</td>
<td>1386</td>
</tr>
</tbody>
</table>

#### CCR New Strategies

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1195</td>
<td>New Strategies in Melanoma: Molecular Testing in Advanced Disease</td>
<td>Scott E. Woodman, Alexander J. Lazar, Kenneth D. Aldape, and Michael A. Davies</td>
<td>1361</td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1201</td>
<td>Molecular Pathways: Beta-Adrenergic Signaling in Cancer</td>
<td>Steven W. Cole and Anil K. Sood</td>
<td>1367</td>
</tr>
<tr>
<td>1207</td>
<td>Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer</td>
<td>Asis Palazón, Julián Aragónés, Aizea Morales-Kastresana, Manuel Ortiz de Landázuri, and Ignacio Melero</td>
<td>1372</td>
</tr>
</tbody>
</table>

#### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1214</td>
<td>Here, There Be Dragons: Charting Autophagy-Related Alterations in Human Tumors</td>
<td>Chandra B. Lebovitz, Svetlana B. Bortnik, and Sharon M. GORSKI</td>
<td></td>
</tr>
</tbody>
</table>

### HUMAN CANCER BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1227</td>
<td>Activation of PI3K Signaling in Merkel Cell Carcinoma</td>
<td>Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barría, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethion, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, and Dora Díaz-Santagata</td>
<td>1303</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1268</td>
<td>Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb</td>
<td>Takeshi Miyazaki, Yang Pan, Kaushal Joshi, Deepthi Purohit, Bin Hu, Habibe Demir, Sarmitshu Mazumder, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, and Ichiro Nakano</td>
<td>1372</td>
</tr>
</tbody>
</table>
SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer
Won Gu Kim, Celine J. Guigon, Laura Fozzatti, Jeong Won Park, Changxue Lu, Mark C. Willingham, and Sheue-yann Cheng

Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma
Yang Xu, Venugopal Chenna, Chaoxin Hu, Hai-Xiang Sun, Mehtab Khan, Haibo Bai, Xin-Rong Yang, Qin-Feng Zhu, Yun-Fan Sun, Anirban Maitra, Jia Fan, and Robert A. Anders

Polymerized Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma

IMAGING, DIAGNOSIS, PROGNOSIS

[18F]FLT–PET Imaging Does Not Always "Light Up" Proliferating Tumor Cells
Cathy C. Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpitz, Cory L. Painter, Qin Zhang, Patrick B. Lappin, Tim Nichols, Maruja E. Lira, Kenneth Zasadny, Kenneth J. O'Brien, Dana Buckman, Anthony Wong, and James G. Christensen

Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture
Juliette Thariat, Marie-Christine Etienne-Grimaldi, Dominique Grall, René-Jean Bensadoun, Anne Cayre, Frédérique Penault-Llorca, Laurence Veracini, Mireille Francoual, Peter O'Brien, Dana Buckman, Anthony Wong, and James G. Christensen

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Markus Riester, Jennifer M. Taylor, Andrew Feifer, Theresa Koppie, Jonathan E. Rosenberg, Robert J. Downey, Bernard H. Bochner, and Franziska Michor

Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability
Aimee M. Crago, Nicholas D. Socci, Penelope DeCarolisi, Rachael O’Connor, Barry S. Taylor, Li-Xuan Qin, Cristina R. Antonescu, and Samuel Singer

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Hatem A. Azim Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmine Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiriou, and Sherene Loi

Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Timothy R. Donahue, Linh M. Tran, Reginald Hill, Yunfeng Li, Anne Kovochich, Joseph H. Calvopina, Sanjeet G. Patel, Napang Wu, Anreas Hindoyan, James J. Farrell, Xinmin Li, David W. Dawson, and Hong Wu

Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression
Tobias Lange, Sebastian Ullrich, Imke Müller, Michael F. Nentwich, Katrin Stübke, Susanne Feldhaus, Christine Knes, Olaf J.C. Hellwinkel, Robert L. Vessella, Claudia Abramjuk, Mario Anders, Jennifer Schröder-Schwarz, Thorsten Schomm, Hartwig Huland, Guido Sauter, and Udo Schumacher

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilnott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, and Richard A. Scolyer

Results of a Phase I Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Andres Forero-Torres, Sven de Vos, Brad L. Pohlman, Maxim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, and Kristen N. Ganjoo

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

David S. Yoo, John P. Kirkpatrick, Oma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Dunphy, Neal E. Ready, and David M. Brizel

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors


Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

Kimberly Noonan, Lakshmi Rudraraju, Anna Ferguson, Amy Emerling, Marcela F. Pasetti, Carol A. Huff, and Ivan Borrello

A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck


CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma

Kesuke Aoe, Vihwa Jeet Amatys, Nobukazu Fujimoto, Kii Ohnuma, Osamu Hosono, Akio Hiroki, Masanori Fujii, Taketo Yamada, Nam H. Dang, Yukio Takeshima, Kouki Inai, Takumi Kishimoto, and Chikao Morimoto

Sunitinib Therapy for Melanoma Patients with KIT Mutations

David R. Minor, Mohammed Kashani-Sabet, Maria Garrido, Steven J. O’Day, Omid Hamid, and Boris C. Bastian

Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer

Julie K. Schwarz, Jacqueline E. Payton, Ramachandran Rashmi, Tao Xiang, Yunhe Jia, Phylis Huetttner, Buck E. Rogers, Qin Yang, Mark Watson, Janet S. Rader, and Perry W. Grigsby

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew J. Weickhardt, Kimi L. Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella-Garcia, and D. Ross Camidge

Correction: Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Correction: Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
ABOUT THE COVER

Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.